How Do We Actually Meet the Needs of the Evolving Life Science Workforce?

Published on :

A recent panel discussion at Bisnow’s May Mid-Atlantic Life Sciences & Biotech event further emphasized the point that we’ve been hearing time and time again – we need to do more to support and adequately prepare the workforce to fill not only the current life science positions but future needs as well.

Baltimore MedTech Sector a Key Asset for Ascending Biotech Cluster, Part One

Published on :

BioBuzz has been reporting on myriad medtech university system spinouts and maturing companies from the Baltimore area for a number of years; we’ve featured a number of exciting and promising individual companies. However, as we’ve stepped back a bit to examine more recent Baltimore biohub developments, it’s become clear that there is an unmistakable groundswell of medtech activity that’s transforming the Baltimore life sciences sector.

Terran Biosciences and University of Maryland, Baltimore announce exclusive licensing deal for a portfolio of patents and data supporting novel innovation in the psychedelic therapeutic space

Published on :

Terran Biosciences, Inc. (“Terran”) has entered into an agreement with the University of Maryland, Baltimore (“UMB”) for a worldwide exclusive license to develop and commercialize a portfolio of UMB’s patents and data to support a novel approach to the treatment of neurological and psychiatric illnesses with psychedelic therapeutics.

University of Maryland, Baltimore (UMB) Grants GlycoMantra Exclusive License to Advance the Company’s Therapeutic Pipeline

Published on :

GlycoMantra, a University of Maryland, Baltimore (UMB) startup company developing therapeutics for unmet medical needs in prostate cancer, NASH liver fibrosis, and type 2 diabetes, has been granted worldwide, exclusive rights to a UMB technology to advance the company’s pipeline of therapeutics for treating drug-resistant metastatic colorectal cancer (mCRC).

Anchor Ventures Shares Resources for Aspiring Entrepreneurs

Published on :

The BioHealth Capital Region (BHCR) continues to establish itself as the go-to hub for biotech startups and corporations. As we previously reported, BHCR startups secured important investment in 2019, including venture funding and IPOs of more than $739M in total investment raised. To keep the momentum strong and ensure that BHCR startups are set up for success, our region must develop and implement a robust infrastructure and network that enables innovative ideas to progress from research and invention to market commercialization. 

Maryland Commerce Supports Research Professorships at Eight Higher Education Institutions

Published on :

The Maryland Department of Commerce joined eight local colleges and universities in endowing a total of $21.2 million to fund a dozen new research professorships. The endowments were made through the Maryland E-Nnovation Initiative (MEI), a state program created to spur basic and applied research in scientific and technical fields at the colleges and universities. The schools raised a total of more than $10.6 million in private funding for each chair and Maryland Commerce approved matching grants of $10.6 million to support the endowments.

National Science Foundation Issues Small Business Innovation Research (SBIR) Grant to The Wrightguard Innovations Corporation in Support of Novel Mouthguard Technology

Published on :

The WrightGuard Innovations Corporation (TWGIC), a University of Maryland, Baltimore (UMB) startup company developing smart mouthguard technology designed to protect athletes, announced today that the National Science Foundation (NSF) has awarded the company an SBIR grant totaling more than $250K.

University of Maryland, Baltimore (UMB) Grants Pumas-AI Exclusive License of Analytics Platform to Enhance Drug Development

Published on :

Pumas-AI, a University of Maryland, Baltimore (UMB) startup company, has been granted worldwide, exclusive rights to enhancements to Pumas, an end-to-end pharmaceutical modeling and simulation platform for quantitative analysis across the drug development lifecycle. Pumas 2.0 builds on the company’s existing platform, which also employs technology licensed from UMB.